Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing.
The Cambridge, MA-based company announced Thursday that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.